Macrophage Activation Syndrome as Onset of Systemic Lupus Erythematosus: A Case Report and a Review of the Literature [PDF]
, 2015 Macrophage activation syndrome (MAS) is a potentially fatal condition. It is a rare complication of several autoimmune disorders, including systemic lupus erythematosus (SLE) and systemic juvenile idiopathic arthritis (sJIA).
Didona, Dario +4 more
core +4 more sources
Anakinra reduces lung inflammation in experimental acute lung injury
Immunity, Inflammation and Disease, 2022 Introduction Acute respiratory distress syndrome (ARDS) is a severe form of acute lung injury (ALI) resulting in life‐threatening hypoxaemia. Although ARDS can be caused by a variety of pathogens or major trauma, it is best known as the major cause of ...
Paul Engeroff +3 more
doaj +1 more source
National Institute for Clinical Excellence and its value judgments [PDF]
, 2004 The National Institute for Clinical Excellence (NICE) offers health professionals in England and Wales advice on providing NHS patients with the highest attainable standards of care.
Culyer, A.J., Rawlins, M.D.
core +2 more sources
Continuous IV infusion of anakinra
Frontiers in Pharmacology, 2023 Objective: A review of the use of continuous IV infusion of anakinra; a description of the protocol for continuous IV infusion of anakinra in the treatment of cytokine storm developed over the past 4 years at a tertiary level academic medical center in ...
Brittney N. Saunders +3 more
semanticscholar +1 more source
Candida albicans colonization and dissemination from the murine gastrointestinal tract : the influence of morphology and Th17 immunity [PDF]
, 2014 This article is protected by copyright. All rights reserved. This work was supported by the Wellcome Trust (086558, 080088, 102705), a Wellcome Trust Strategic Award (097377) and a studentship from the University of Aberdeen. D.K.
Brown, Alistair J P +9 more
core +1 more source
Viruses, 2023 (1) Background: Some severe COVID-19 patients develop hyperinflammatory cytokine storm syndrome (CSS). We assessed the efficacy of anakinra added to standard of care (SoC) in hospitalized COVID-19 CSS patients.
Lesley E. Jackson +6 more
doaj +1 more source
Protective effect of anakinra on audiovestibular function in a murine model of endolymphatic hydrops
Frontiers in Cellular Neuroscience, 2022 IntroductionMénière’s disease (MD), a common disease in the inner ear, is characterized by an increase in endolymph in the cochlear duct and vestibular labyrinth. The pathophysiology of the condition appears to be the immune response.
Na Zhang +41 more
doaj +1 more source
Inhibition of interleukin-1 signaling enhances elimination of tyrosine kinase inhibitor treated CML stem cells [PDF]
, 2016 Treatment of chronic myelogenous leukemia (CML) with BCR-ABL tyrosine kinase inhibitors (TKI) fails to eliminate leukemia stem cells (LSC). Patients remain at risk for relapse, and additional approaches to deplete CML LSC are needed to enhance the ...
Agarwal, Puneet +9 more
core +1 more source
Systematic review and meta-analysis of anakinra, sarilumab, siltuximab and tocilizumab for COVID-19
Thorax, 2021 Background There is accumulating evidence for an overly activated immune response in severe COVID-19, with several studies exploring the therapeutic role of immunomodulation.
F. Khan +6 more
semanticscholar +1 more source
Anakinra treatment in critically ill COVID-19 patients: a prospective cohort study
Critical Care, 2020 Background A subset of critically ill COVID-19 patients develop a hyperinflammatory state. Anakinra, a recombinant interleukin-1 receptor antagonist, is known to be effective in several hyperinflammatory diseases.
Emma J. Kooistra +11 more
doaj +1 more source